APA (7th ed.) Citation

Z, Q., T, H., W, F., M, K., K, P., R, S., . . . S, K. (2025). Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies. Archives of pathology & laboratory medicine, 149(6), 542. https://doi.org/10.5858/arpa.2024-0014-OA

Chicago Style (17th ed.) Citation

Z, Qi, et al. "Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies." Archives of Pathology & Laboratory Medicine 149, no. 6 (2025): 542. https://doi.org/10.5858/arpa.2024-0014-OA.

MLA (9th ed.) Citation

Z, Qi, et al. "Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies." Archives of Pathology & Laboratory Medicine, vol. 149, no. 6, 2025, p. 542, https://doi.org/10.5858/arpa.2024-0014-OA.